



RECEIVED

MAY 06 2003

TECH CENTER 1600/2000

FORM PTO-1449		ATTY. DOCKET NO. 0609.4550001/JAG/FRC	APPLICATION NO. 09/956,980
<u>FIRST SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
16	AR	66	Cardelli, M.B., et al., "Chelation Therapy. Unproved Modality in the Treatment of Alzheimer-Type Dementia," <i>J. Am. Geriatr. Soc.</i> 33:548-551, Blackwell Science (1985)				
16	AS	66	Ishii, T., and Bannai, S., "The Synergistic Action of the Copper Chelator Bathocuproine Sulphonate and Cysteine in Enhancing Growth of L1210 Cells In Vitro," <i>J. Cell. Physiol.</i> 125:151-155, Alan R. Liss, Inc. (1985)				
16	AT	66	Kluck, T.P.A., et al., "Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation," <i>Clin. Pharmacol. Ther.</i> 48:439-446, Mosby-Year Book (1990)				

EXAMINER	16 - Wecklitz	DATE CONSIDERED	3.3.04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



RECEIVED

MAY 06 2003

TECH CENTER 1600/2900

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4550001/JAG/FRC	APPLICATION NO. 09/956,980
		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>W</i>	AR	<u>67</u>	'9579. Trientine," in The Merck Index: An encyclopedia of chemicals, drugs, and biologicals, 11 th edition, Budavari, S., et al., eds., Merck & Co., Inc., Rahway, N.J., p. 1521 (1989)				
<i>W</i>	AS	<u>67</u>	Van Reyk, D.M., and Dean, R.T., "The Iron-selective Chelator Desferal Can Reduce Chelated Copper," Free Radic. Res. 24:55-60, Harwood Academic Publishers GmbH (January 1996)				
<i>W</i>	AT	<u>67</u>	Dialog File 351, Accession No. 8749401, Derwent WPI English language abstract for DE 40 04 978 A1 (Document AM4)				

EXAMINER	<i>W. Wiedenfels</i>	DATE CONSIDERED	<i>3-3-04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			




FORM PTO-1449 <u>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.455001/JAG/FRC	APPLICATION NO. 09/956,980
		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
(C)	AH2	6,323,218 B1	11/27/2001	Bush et al.			03/11/1998
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
(C)	AR	68	Cherny, R.A., et al., "Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice," <i>Neuron</i> 30:665-676, Cell Press (2001)				
(C)	AS	68	Cherny, R.A., et al., "Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease," <i>J. Struct. Biol.</i> 130:209-216, Academic Press (2000)				
(C)	AT	68	Kisilevsky, R., and Fraser, P.E., "A β Amyloidogenesis: Unique, or Variation on a Systemic Theme?" <i>Crit. Rev. Biochem. Mol. Biol.</i> 32:361-404, CRC Press LLC (1997)				

EXAMINER	(C) - <i>Weldsleef</i>	DATE CONSIDERED	3-3-04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.455001/JAG/FRC	APPLICATION NO. 09/956,980
		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>GW</i>	AR	<u>69</u>	Maury, C.P.J., "Molecular Pathogenesis of β -Amyloidosis in Alzheimer's Disease And Other Cerebral Amyloidoses," <i>Lab. Invest.</i> 72:4-16, The United States and Canadian Academy of Pathology, Inc. (1995)
<i>CC</i>	AS	<u>69</u>	Gnjec, A., et al., "Transition Metal Chelator Therapy-A Potential Treatment for Alzheimer's Disease?" <i>Front. Biosci.</i> 7:d1016-1023, Frontiers in Bioscience Publications (2002)
<i>HW</i>	AT	<u>69</u>	Fonte, J., et al., "The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid- β Levels: Resolubilization of amyloid- β with transition metal ion chelators," <i>J. Alzheimer's Dis.</i> 3:209-219, IOS Press (2001)

EXAMINER	<i>W. Weis</i>	DATE CONSIDERED	<i>308</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449 <u>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609-455001/JAG/FRC	APPLICATION NO. 09/956,980
		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

NOV 19 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>AC</i>	AR	<u>70</u>	Gillmore, J.D., et al., "Amyloidosis: A Review of Recent Diagnostic and Therapeutic Developments," <i>Br. J. Haematol.</i> 99:245-256, Blackwell Science Ltd. (1997)
<i>AC</i>	AS	<u>70</u>	Schnabel, J., "New Alzheimer's Therapy Suggested," <i>Science</i> 260:1719-1720, The American Association for the Advancement of Science (1993)
<i>AC</i>	AT	<u>70</u>	"Bathocuprione," <i>Biochemicals, Organic Compounds, Diagnostic Reagents</i> , pg. 149, catalog #B1000, Sigma Chemical Co. (1995)

EXAMINER	<i>AC</i> <i>AC</i>		DATE CONSIDERED 3-3-04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.455001/JAG/FRC

APPLICATION NO.
09/956,980

APPLICANT
Bush et al.

FILING DATE
September 21, 2001

GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>SC</i>	AR	<u>71</u>	Goodman, L.S., and Gilman, A., "Drug Absorption, Bioavailability, and Routes of Administration," in Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , Eighth Edition, McGraw-Hill, Inc., New York, NY, pp.5-6 (1993)
	AS		
	AT		

EXAMINER	<i>SC</i> <i>W. L. Et al.</i>	DATE CONSIDERED <i>3-3-04</i>
----------	-------------------------------	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
NOV 19 2003
TECH CENTER 1600/2900



RECEIVED

MAY 06 2003

TECH CENTER 1600/2000

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4550001/JAG/FRC	APPLICATION NO. 09/956,980
		APPLICANT Bush et al.	
		FILING DATE September 21, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
(W)	AF2 4,419,365	12/06/1983	McLachlan			12/21/1983
(W)	AG2 5,310,936	05/10/1994	Regtop et al.			01/15/1992
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
(W)	AM4 DE 40 04 978 A1	08/22/1991	Germany			X Yes No
	AN4 WO 94/27594 A2	12/08/1994	WIPO			Yes No
	AO4 WO 96/39144 A1	12/12/1996	WIPO			Yes No
(W)	AP4 WO 97/01559 A1	01/16/1997	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR			
AS			
(W)	AT 65	BIOMOL Product Data for TPEN, Catalog No. AP-300, BIOMOL Research Laboratories, Inc. Plymouth Meeting, PA	

EXAMINER	<i>W. Wedderburn</i>		DATE CONSIDERED 3-3-04
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		